Use of global assays to understand clinical phenotype in congenital factor VII deficiency

Haemophilia

Volumn 19, Issue 5, 2013, Pages 765-772

  Greene, L A ^a,f   Goldenberg, N A ^b,g,h   Simpson, M L ^c   Villalobos Menuey, E ^b   Bombardier, C ^b   Acharya, S S ^d   Santiago Borrero, P J ^e   Cambara, A ^e   Dimichele, D M ^a,i  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Northwell Health   (United States)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Clot formation; Factor VII deficiency; Fibrinolysis; Global assay; Plasmin generation; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 7; PLASMIN; THROMBIN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLOT FORMATION AND FIBRINOLYSIS GLOBAL ASSAY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; MEDICAL RECORD REVIEW; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; SCHOOL CHILD; SIMULTANEOUS THROMBIN AND PLASMIN GENERATION GLOBAL ASSAY; THROMBIN TIME; VELOCITY;

CLOT FORMATION; FACTOR VII DEFICIENCY; FIBRINOLYSIS; GLOBAL ASSAY; PLASMIN GENERATION; THROMBIN GENERATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FACTOR VII DEFICIENCY; FEMALE; FIBRINOLYSIS; HEMORRHAGE; HUMANS; MALE; PHENOTYPE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84883051457     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12160     Document Type: Article

References (29)

1. Shapiro AD, Soucie JM, Peyvandi F, ASchman DJ, DiMichele DM. Kowledge and therapeutic gaps a public health problem in a rate coagulation disorders population. Am J Prev Med 2011; 41: S324-31.
2. Peyvandi F, Palla R, Menegatti M et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorderes: results from the European network of rate bleeding disorders. J Thromb Haemost 2012; 10: 615-21.
3. Acharya SS, Coughlin A, DiMichele DM. Rare bleeding disorder registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2: 248-56.
4. Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35: 400-6.
5. Mariani G, Herrman FH, Dolce A, Batorova A, Etro D, Peyvandi F et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-7.
6. Girolami A, Tezza F, Scandellari R, Vettore S, Girolami B. Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenial FVII deficiency. Critical review of the literature. J Thromb Thrombolysis 2010; 30: 172-8.
7. Gainsily-Blaizot M, Verdier R, Biron-Adreani C et al. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk? Haemotologica 2004; 89: 704-9.
8. He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma: method design and preliminary results. Thromb Res 1999; 96: 145-56.
9. Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johson MJ. A new euglobin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112: 329-37.
10. Chitlur M. Challenges in the laboratory analyses of bleeding disorders. Thromb Res 2012; 130: 1-6.
11. Van Geffen M, Van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res 2012; 129: 681-7.
12. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelestography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012; 26: 1-13.
13. Goldenberg NA, Hathaway WE, Jcobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res 2005; 116: 345-56.
14. Goldenberg NA, Hathaway WE, Jacobson L, McFarland K, Manco-Johnson MJ. Influence of factor VIII on overall coagulability and fibrinolytic potential of hameophilia plasma as measured by global assay: monitoring in haemophilia A. Haemophilia 2006; 12: 605-14.
15. Goldenberg NA, Bombardier C, Hathaway WE, McFarland K, Jocobson L, Manco-Johnson MJ. Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B. Haemophilia 2008; 14: 68-77.
16. Bombardier C, Villalobos-Menuey E, Ruegg K, Hathaway WE, Manco-Johnson MJ, Goldenberg NA. Monitoring hypercoagulability and fibrinolysis following acute venous thromboembolism in children: application of the CloFAL assay in prospective inception cohort study. Thromb Res 2012; 130: 343-9.
17. Simpson MD, Goldenberg NA, Jocobeson LJ, Christopher BG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res 2011; 127: 317-23.
18. Peyvandi F, DiMichele DM, Bolton-Maggs HB, Lee CA, Tripodi A. Classification of rare bleeding disorders (RBD) based on asscoation between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10: 1938-43.
19. Giansily-Blazot M, Raed AD, Schved J. Thrombin generation measurement in factor VII-depleted plasmas compared to inherited factor VII-deficient plasmas. Pathophysiol Haemost Thromb 2003; 33: 36-42.
20. Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008; 99: 767-73.
21. Bollinger D, Szlam E, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Haemophilia 2010; 16: 510-7.
22. Taketomi T, Szlam F, Bader SO, Sheppard CA, Levy JH, Tanaka KA. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. Blood Coagul Fibrinolysis 2008; 19: 135-41.
23. Bauma BN, Mosnier Lo. Thrombin activatable fibrinolysis inhibitor (TAFI)- how does thrombin regulate fibrinolysis? Ann Med 2006; 38: 378-88.
24. Broze GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
25. Foley JH, Cook PF, Nesheim MR. Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites. J Biol Chem 2011; 286: 19280-6.
26. Foley JH, Karl-Uwe P, Rea CJ et al. Solulin increases clot stability in whole blood from humans and dogs with hemophilia. Blood 2012; 119: 3622-8.
27. Rodeghiero F, Tosetto A, Abshire T et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 2063-5.
28. Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9: 1143-8.
29. Batorova A, Napolitano M, Dolce A et al. At disease presentation, severity of the bleeding symptom predicts the following bleedings in patients with FVII deficiency. Blood 2011; 118: 30.